Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.

The absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) through different routes was evaluated by determining the ovulation-inducing activity in diestrous rats. Vaginal administration showed the greatest potency among nonparenteral routes and was followed successively by rectal, nasal, and oral administration. Mixed micellar solution with monoolein-bile acids improved the intestinal absorption of leuprolide, and nasal absorption was enhanced by adding sodium glycocholate, surfactin, or polyoxyethylene 9 lauryl ether, but these bioavailabilities were still insufficient. The vaginal absorption was enhanced by organic acids: citric, succinic, tartaric, and glycocholic; the absolute bioavailability increased to approximately 20%. The vaginal absorption from jellies, as practical dosage forms, yielded sufficient activity of leuprolide, but absorption was slightly reduced with highly polar polymers or with higher concentrations of polymers. It was concluded that vaginal administration of leuprolide can be a rational dosage method for a long-term antitumor therapy.

[1]  U. Banik,et al.  Ovulation induction and antifertility effects of an LH-RH analogue (AY 25,205) in cyclic rats. , 1975, Journal of reproduction and fertility.

[2]  C. Beattie,et al.  Post-coital contraceptive effects of an agonistic analogue of luteinizing hormone releasing hormone. , 1976, Endocrine research communications.

[3]  J. Pasteels,et al.  Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. , 1977, European journal of cancer.

[4]  C. Bergquist,et al.  Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control? , 1978, Contraception.

[5]  A. Schally,et al.  Gonadotropin-releasing activity of two highly active and long-acting analogs of luteinizing hormone-releasing hormone after subcutaneous, intravaginal, and oral administration. , 1975, Fertility and sterility.

[6]  J. Thorell,et al.  Letter: Intranasal administration of synthetic gonadotrophin-releasing hormone. , 1973, British medical journal.

[7]  H. Burger,et al.  RADIOIMMUNOASSAY OF SERUM LUTEINIZING HORMONE RELEASING HORMONE (LH‐RH) AFTER INTRA‐NASAL ADMINISTRATION AND EVALUATION OF THE PITUITARY GONADOTROPHIC RESPONSE , 1974, Clinical endocrinology.

[8]  A. Kastin,et al.  Prolonged elevation of luteinizing hormone (LH) after intranasal administration of an analog of LH-releasing hormone. , 1976, Fertility and sterility.

[9]  Y. Takatsuka,et al.  Effect of surfactants on the nasal absorption of insulin in rats , 1981 .

[10]  W. White,et al.  Regression of rat mammary tumors effected by a gonadoliberin analog. , 1976, Cancer research.

[11]  A. Kastin,et al.  SUPPRESSION OF GONADOTROPHIN RELEASE IN MAN BY AN INHIBITORY ANALOGUE OF L.H.-RELEASING HORMONE , 1977, The Lancet.

[12]  M. Fujino,et al.  Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. , 1974, Biochemical and biophysical research communications.

[13]  Muranishi Shozo,et al.  Improvement of absolute bioavailability of normally poorly absorbed drugs: inducement of the intestinal absorption of streptomycin and gentamycin by lipid-bile salt mixed micelles in rat and rabbit , 1979 .

[14]  A. Dulhunty,et al.  Low resistance junctions in crayfish. Structural changes with functional uncoupling , 1976, The Journal of cell biology.

[15]  H. Solbach,et al.  Intranasal application of luteinising-hormone releasing hormone. , 1973, Lancet.

[16]  H. Schneider,et al.  Linear Dose Dependent LH Release Following Intranasally Sprayed LRH , 1974, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  D. Heber,et al.  Male contraception; synergism of gonadotropin-releasing hormone analog and testosterone in suppressing gonadotropin. , 1980, Science.

[18]  A. Kakinuma,et al.  Surfactin, a crystalline peptidelipid surfactant produced by Bacillus subtilis: isolation, characterization and its inhibition of fibrin clot formation. , 1968, Biochemical and biophysical research communications.

[19]  A. Kastin,et al.  STIMULATION OF LUTEINISING HORMONE (L.H.) RELEASE AFTER ORAL ADMINISTRATION OF AN ANALOGUE OF L.H. RELEASING HORMONE , 1975, The Lancet.

[20]  G. Flynn,et al.  Systems approach to vaginal delivery of drugs II: In situ vaginal absorption of unbranched aliphatic alcohols. , 1976, Journal of pharmaceutical sciences.

[21]  G. Fink,et al.  Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration. , 1974, The Journal of endocrinology.

[22]  A. Schally,et al.  Stimulation of luteinizing hormone (LH) and follicle-stimulating hormone by (D-Leu6, des-Gly10-NH2)-LH-releasing hormone ethylamide after subcutaneous, intravaginal, and intrarectal administration to women. , 1977, Fertility and sterility.

[23]  W. White,et al.  Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. , 1976, Science.

[24]  R. Lambe,et al.  CONTRACEPTIVE PROPERTIES OF LUTEINISING HORMONE RELEASING HORMONE , 1979, The Lancet.